Autosomal Recessive Axonal Charcot-Marie-Tooth Disease due to a Copper-Metabolism Defect

Autosomal recessive axonal Charcot-Marie-Tooth disease due to a copper-metabolism defect is a very rare inherited nerve disease. It mainly damages the long “wires” (axons) of the peripheral nerves—the nerves that carry signals to and from the arms and legs. Children usually start to show signs in infancy or childhood. They may have slow or lost motor milestones, weak muscles, thin (wasted) muscles, and absent deep-tendon reflexes in the legs and later in the arms. Some children also have mild loss of vibration sense and, in some reports, facial muscle weakness or twitching. The key biological problem is a fault in how cells handle copper, a mineral that nerve cells use to run energy-making machinery in mitochondria. When copper handling fails, a mitochondrial enzyme called cytochrome-c oxidase (complex IV) does not work well, and axons slowly lose function. Rare Diseases Information Center+2Orpha+2

Autosomal recessive axonal Charcot-Marie-Tooth (CMT) due to a copper-metabolism defect is a hereditary nerve disease where both copies of a gene are changed (one from each parent). The defect disrupts how cells handle copper for building cytochrome-c oxidase (complex IV) in mitochondria. When this copper-dependent assembly falters (for example with SCO2 mutations), the longest peripheral nerves degenerate (“axonal” neuropathy). Children usually develop weakness and wasting of foot and hand muscles, high arches, and walking problems that slowly worsen. Although CMT includes many genetic types, this copper-linked, recessive axonal form is rare. PMC+2NCBI+2

In this form, the problem is not body-wide copper deficiency in the diet, but cellular handling of copper inside mitochondria. Copper-binding proteins (e.g., SCO2) help insert copper into complex IV; when they fail, energy production drops and long axons are especially vulnerable, leading to distal weakness, numbness, reduced reflexes, and foot deformities. Other mitochondrial assembly genes (e.g., COX6A1) can also cause recessive axonal or mixed CMT, highlighting the mitochondrial link. PMC+2OUP Academic+2

Because the longest nerves are affected first, early signs often include tripping, ankle sprains, toe walking, and difficulty running. Hand weakness may follow later. Many people need ankle-foot orthoses (AFOs) for foot-drop. The condition is genetically confirmed by sequencing panels that include CMT genes (>90 known genes). Nerve conduction studies show axonal patterns (reduced amplitudes), and imaging/ultrasound can document nerve and foot changes. clinicalgenome.org+2NCBI+2

Scientists have linked this condition to harmful (pathogenic) variants in SCO2, a mitochondrial copper-binding protein needed to assemble cytochrome-c oxidase. Families with two faulty SCO2 copies (one from each parent) can develop an early-onset axonal CMT picture—often placed within the “CMT4” (recessive) group. Lab studies from patient cells show reduced SCO2 protein, low cellular copper, and complex-IV deficiency—direct evidence that copper biology drives the nerve problem. Related copper-transport genes (like ATP7A) can also cause CMT-like neuropathies, underscoring the copper link, though ATP7A diseases follow different inheritance (X-linked) and clinical patterns. NCBI+3PMC+3PubMed+3

Other names

• “Autosomal recessive axonal CMT due to copper metabolism defect”

• “CMT type 4 associated with copper metabolism”

• “SCO2-related early-onset axonal Charcot-Marie-Tooth disease”

• “Hereditary motor and sensory neuropathy (axonal) due to copper defect”
  These labels all refer to the same concept: a recessive axonal CMT whose mechanism involves cellular copper handling (especially SCO2). Orpha+2Rare Diseases Information Center+2

Types

Because this is rare, experts usually “type” it by age of onset, severity, and extra features, rather than many separate subtypes:

1. Infant- or early-childhood onset, motor-predominant axonal neuropathy. First clues are delayed walking, frequent falls, or regression of motor skills. Nerve studies show axonal loss more than demyelination. Rare Diseases Information Center

2. Childhood onset with mild sensory loss. Vibration sense may be slightly reduced; weakness and areflexia are clearer than numbness. Rare Diseases Information Center

3. Phenotypes with cranial-nerve involvement. Some reports include facial weakness or fasciculations. Rare Diseases Information Center

4. SCO2-confirmed cases (“CMT4, axonal”). These carry biallelic SCO2 variants, show copper deficiency at the cellular level, and COX (complex IV) deficiency. PMC+1

(Clinically, this sits within the broader CMT spectrum, which includes many genetic subtypes; axonal forms are commonly labeled “CMT2,” but recessive axonal forms are often grouped under “CMT4.”) NCBI

Causes

Because this is a single rare disease entity, “causes” here means ways the biology can be disrupted—from exact genetic variants to the cellular consequences. Items 1–8 are direct primary causes; 9–20 are well-supported mechanistic contributors/modifiers grounded in copper biology and COX assembly in nerves.

1. Biallelic pathogenic variants in SCO2. This is the best-supported direct cause of early-onset axonal CMT with cellular copper deficiency. PMC+1

2. Missense changes in the SCO2 copper-binding/loop region (for example, pairs like E140K with P169T or D135G with R171Q) that destabilize the protein and lower cellular copper. PubMed

3. SCO2 variants causing reduced protein levels in patient fibroblasts, leading to cytochrome-c oxidase deficiency. PubMed

4. Loss-of-function SCO2 variants (nonsense, frameshift, splice) predicted to impair complex-IV assembly in neurons. (General mechanism inferred from SCO2 function in COX assembly.) PMC

5. Autosomal recessive inheritance with parental carrier status (one variant from each parent), increasing risk in consanguinity. (Inheritance model for SCO2-related disease.) PMC

6. Cellular copper deficiency in neurons—documented in patient cells—impairs mitochondrial enzymes needed for axon health. PMC

7. Complex-IV (COX) deficiency from faulty copper delivery to COX subunits—this starves axons of energy. PMC

8. Failure of copper relay to COX via COX17/SCO1/SCO2 pathway, a known copper-chaperone system that fuels complex-IV. Nature+1

9. Axonal energy crisis and oxidative stress as downstream effects of COX failure in long motor axons. (Mechanistic consequence of COX deficiency in axons.) PMC

10. Mitochondrial network stress in neurons with impaired complex-IV function, promoting axonal degeneration. (Established principle in CMT and mitochondrial neuropathies.) OUP Academic

11. Defects in broader copper-homeostasis networks can exacerbate neuronal stress (reviewed in copper-biology literature). Wiley Online Library+1

12. Inefficient copper trafficking via ATOX1/ATP7 pathways may modify phenotype; ATP7A mutations cause a CMT-like distal motor neuropathy, highlighting pathway sensitivity (though ATP7A disease is X-linked and distinct). NCBI+1

13. Impaired antioxidant defenses when copper-dependent enzymes (e.g., SOD1 via CCS) are secondarily affected, increasing axonal vulnerability. Nature

14. Length-dependent axonal susceptibility (longest nerves fail first), a shared principle across axonal CMT that applies here. NCBI

15. Developmental motor load in early childhood unmasks axonal weakness (walking/running demands reveal deficits). (Clinical observation across CMT.) NINDS+1

16. Possible tissue-specific copper imbalance (low in some tissues, dysregulated in others) reported in copper disorders may influence nerve phenotype. NCBI

17. Genetic background and modifiers within mitochondrial assembly genes can shape severity (evidence from COX-assembly gene literature in CMT). OUP Academic

18. Secondary deconditioning (less activity due to weakness) can amplify disability but is not the primary cause. (CMT care principles.) Mayo Clinic

19. Superimposed illnesses that stress nerves (e.g., poorly controlled diabetes) can worsen neuropathy expression in any CMT, including rare forms. (General CMT guidance.) Mayo Clinic

20. Nutritional copper insufficiency as a theoretical modifier, distinct from the genetic disease, but copper status is biologically relevant to nerve function; not proven to cause this genetic CMT, but conceptually important. Wiley Online Library

Symptoms

1. Slow motor milestones or regression (late walking, trouble running). This often appears first in infancy/childhood. Rare Diseases Information Center

2. Progressive leg weakness (especially foot and ankle), leading to frequent tripping or falls. Rare Diseases Information Center

3. Muscle wasting (thinning) in calves and later hands, reflecting axonal loss. Rare Diseases Information Center

4. Absent or very weak deep-tendon reflexes (ankle, knee; later upper limbs). Rare Diseases Information Center

5. Mild loss of vibration sense at ankles and toes. Rare Diseases Information Center

6. Foot shape changes over time (pes cavus/high arches or hammertoes) as weakness progresses—typical of many CMTs. Mayo Clinic

7. Hand weakness later on, with difficulty with fine tasks. Mayo Clinic

8. Fatigability with walking or stairs due to axonal energy failure. OUP Academic

9. Gait imbalance (worse in the dark) due to sensory and motor axonal loss. NINDS

10. Cramps or muscle twitching, occasionally including facial fasciculations in reported cases. Rare Diseases Information Center

11. Numbness or tingling in feet (often milder than weakness). NINDS

12. Reduced exercise tolerance from neuropathy and deconditioning. Mayo Clinic

13. Frequent ankle sprains from foot drop and poor proprioception. NINDS

14. Calluses or painless wounds on feet from reduced sensation (monitoring is important). Mayo Clinic

15. Variable severity within families, even with the same genotype, which is common in CMTs. NCBI

Diagnostic tests

A) Physical-exam–based (bedside) assessments

1. Detailed neurologic exam. Doctors check strength, reflexes, tone, and sensation. In this disease they often find distal weakness, muscle wasting, and absent ankle/knee reflexes; vibration can be mildly reduced. Rare Diseases Information Center

2. Gait observation and timed walk. Watching heel- and toe-walking, turns, and endurance helps quantify functional impact in axonal CMT. NINDS

3. Foot alignment inspection. High arches or hammertoes suggest chronic distal weakness typical of CMT. Mayo Clinic

4. Cranial-nerve exam. Some cases note facial weakness or fasciculations; checking facial movements can document this feature. Rare Diseases Information Center

B) Simple manual/bedside tests

5. Tuning-fork vibration test (128-Hz). A fast way to detect reduced vibration sense at toes/ankles in axonal neuropathy. Rare Diseases Information Center

6. Romberg test. Standing with feet together and eyes closed screens for sensory ataxia from large-fiber involvement. (Standard neuro exam in neuropathy.) NINDS

7. Manual muscle testing (MRC scale). Grades distal strength (ankle dorsiflexion, plantarflexion, hand intrinsics) to track progression. (CMT care standard.) Charcot-Marie-Tooth Association

8. Functional tests (stair climb, 6-minute walk). Provide objective measures of fatigability and mobility limitations in CMT. (Common functional endpoints in CMT clinics.) Charcot-Marie-Tooth Association

C) Laboratory and pathological tests

9. Genetic testing with a CMT/copper/mitochondrial gene panel, focusing on SCO2 (and, for differential diagnosis, other COX-assembly/copper-pathway genes). Confirms the recessive SCO2 cause when two pathogenic variants are found. PMC+1

10. Targeted SCO2 sequencing if suspicion is high (early-onset axonal CMT plus research/lab hints of cellular copper deficiency). PMC

11. Cellular copper measurement in patient fibroblasts (research/tertiary centers). SCO2-CMT cases showed low cellular copper, supporting the mechanism. (Serum copper may be normal; the key change can be inside cells.) PubMed

12. Cytochrome-c oxidase (complex-IV) activity assays in cells or tissue (specialized labs). Reduced activity supports a copper-dependent mitochondrial assembly defect. PMC

13. Serum copper and ceruloplasmin. These can be checked to review systemic copper status, but they may be normal in SCO2 disease; normal blood tests do not rule out the cellular copper problem. PMC

14. Broader neuropathy labs (B12, thyroid, glucose/A1c, autoimmune screens) are used to exclude look-alikes that can worsen neuropathy but are not the cause here. (Standard CMT differential approach.) NINDS

15. Nerve biopsy (rarely needed). Historical tool that may show axonal loss; today usually reserved for unclear cases after genetics and electrophysiology. (Modern CMT work-ups emphasize genetics over biopsy.) NCBI

D) Electrodiagnostic tests

16. Nerve-conduction studies (NCS). In this condition, motor responses are reduced in size (axonal loss) with relatively preserved conduction speed (not a demyelinating pattern). Sensory responses can be reduced but often less striking than motor. This profile supports axonal CMT. NCBI

17. Electromyography (EMG). Shows chronic denervation/reinnervation in distal muscles, aligning with length-dependent axonal neuropathy. Helpful to stage severity and rule out mimics. NCBI

E) Imaging and other tools

18. MRI of spine/brain (selective). Used to exclude other causes of weakness or hypotonia in young children; CMT itself may have normal CNS imaging. (CMT diagnostic practice.) NINDS

19. Muscle MRI or ultrasound. Can map patterns of distal muscle atrophy/fatty change consistent with chronic neuropathy and help with longitudinal tracking. (Adjunct in CMT clinics.) Charcot-Marie-Tooth Association

20. Gait and balance quantification (instrumented analysis or wearable sensors). Research/tertiary centers use these to measure change over time and response to therapy; useful outcome measures in CMT. Charcot-Marie-Tooth Association

Non-pharmacological treatments (therapies & others)

1) Individualized physiotherapy program (strength + endurance + stretching).
Purpose: Maintain strength, flexibility, and functional mobility.
Mechanism: Progressive resistance and aerobic exercise improve muscle performance and cardiorespiratory fitness; stretching maintains ankle ROM and reduces contracture risk. Evidence in CMT suggests exercise is safe and can improve balance and function when tailored. Wiley Online Library+1

2) Balance and gait training.
Purpose: Reduce falls and improve walking efficiency.
Mechanism: Task-specific drills and cueing enhance sensory integration and compensatory strategies for proprioceptive loss. MDPI

3) Ankle-foot orthoses (AFOs).
Purpose: Treat foot-drop, improve stability, and reduce tripping.
Mechanism: External support positions the ankle for toe-clearance and mid-stance stability; systematic reviews show gait benefits in CMT. PubMed+1

4) Custom foot orthoses and footwear.
Purpose: Off-load pressure points and improve alignment in cavovarus feet.
Mechanism: Posting and arch support redistribute ground reaction forces and improve stance mechanics. RSNA Publications

5) Occupational therapy (hands/ADLs).
Purpose: Maintain independence with tools and joint-protection techniques.
Mechanism: Adaptive strategies/devices reduce strain and compensate for distal weakness. NCBI

6) Fall-prevention home modifications.
Purpose: Reduce injury risk.
Mechanism: Environmental changes (lighting, railings, non-slip mats) address balance/proprioceptive deficits. PubMed

7) Energy-conservation & pacing education.
Purpose: Manage fatigue during daily tasks.
Mechanism: Scheduling rests and prioritizing tasks prevents overwork in weakened motor units. Lippincott Journals

8) Pain neuroscience education & CBT-informed strategies.
Purpose: Reduce pain distress and improve coping.
Mechanism: Reframing pain and graded activity reduce central sensitization components of chronic neuropathic pain. American Academy of Neurology

9) Transcutaneous electrical nerve stimulation (TENS) – optional.
Purpose: Trial adjunct for neuropathic pain.
Mechanism: Segmental inhibition of nociceptive signaling; evidence for neuropathic pain is very low-certainty overall. Cochrane+1

10) Tele-coached home exercise programs.
Purpose: Improve adherence and access.
Mechanism: Remote coaching sustains structured exercise (aerobic, resistance, stretching) shown useful in CMT. Frontiers

11) Hand therapy & splinting.
Purpose: Support pinch/grip and prevent deformity.
Mechanism: Targeted strengthening and stabilizing splints improve function. NCBI

12) Night splints/calf stretching.
Purpose: Prevent Achilles contracture.
Mechanism: Sustained low-load stretch maintains dorsiflexion. Lippincott Journals

13) Progressive resistance training (supervised).
Purpose: Increase proximal muscle strength safely.
Mechanism: Carefully dosed PRE improved strength in pediatric CMT in RCTs. ScienceDirect

14) Aerobic conditioning (low-impact).
Purpose: Enhance endurance and reduce fatigue.
Mechanism: Improves mitochondrial efficiency and walking capacity. Wiley Online Library

15) Skin/foot care education.
Purpose: Prevent ulcers/calluses on insensate feet.
Mechanism: Routine inspection and proper shoes reduce breakdown. RSNA Publications

16) Weight management & nutrition counseling.
Purpose: Reduce joint load and metabolic stress.
Mechanism: Healthy weight supports gait mechanics and energy balance. Lippincott Journals

17) Assistive devices (sticks, walkers) when needed.
Purpose: Improve safety during community ambulation.
Mechanism: Off-loads unstable joints and augments balance. PubMed

18) Orthotist follow-up for AFO comfort/compliance.
Purpose: Optimize wear time and comfort.
Mechanism: Adjustments improve satisfaction and reduce pressure sores. PMC

19) School/workplace accommodations.
Purpose: Preserve participation and productivity.
Mechanism: Ergonomics, task modification, and schedule flexibility mitigate fatigue. Lippincott Journals

20) Pre-surgical rehabilitation (“prehab”).
Purpose: Prepare for possible foot-reconstruction and speed recovery.
Mechanism: Strength, ROM, and gait training before surgery improve postoperative outcomes. PMC

---

Drug treatments

1) Pregabalin (Lyrica).
Class: Gabapentinoid. Dose/Time: Commonly 150–600 mg/day in divided doses as tolerated. Purpose: Neuropathic pain reduction. Mechanism: Binds α2δ subunit of voltage-gated calcium channels to reduce excitatory neurotransmitter release; FDA-approved for DPN. Side effects: Dizziness, somnolence, weight gain, edema. FDA Access Data

2) Duloxetine (Cymbalta).
Class: SNRI. Dose/Time: Often 60–120 mg/day. Purpose: Neuropathic pain and mood symptoms. Mechanism: Inhibits serotonin/norepinephrine reuptake; approved for DPN pain. Side effects: Nausea, dry mouth, hyperhidrosis, possible BP changes. FDA Access Data

3) Gabapentin (Neurontin).
Class: Gabapentinoid. Dose/Time: Titrate from 300 mg qHS to 900–3600 mg/day in divided doses. Purpose: Neuropathic pain (off-label for many neuropathies). Mechanism: α2δ calcium-channel modulation. Side effects: Drowsiness, ataxia, edema. FDA Access Data

4) Lidocaine 5% patch (Lidoderm).
Class: Topical sodium-channel blocker. Dose/Time: Up to 12 h on/12 h off on painful area. Purpose: Focal neuropathic pain/allodynia. Mechanism: Local Na⁺ channel blockade reduces ectopic firing. Side effects: Local skin reactions. FDA Access Data

5) Capsaicin 8% patch (Qutenza).
Class: TRPV1 agonist (defunctionalization). Dose/Time: Applied in clinic every ~3 months to painful area. Purpose: Localized neuropathic pain. Mechanism: High-concentration capsaicin reduces nociceptor function. Side effects: Application-site pain/erythema. FDA Access Data

6) Tapentadol ER (Nucynta ER).
Class: μ-opioid agonist + norepinephrine reuptake inhibitor. Dose/Time: Titrate per label. Purpose: Moderate-to-severe pain; has a DPN indication. Mechanism: Dual action reduces neuropathic pain signaling. Side effects: Nausea, constipation, sedation; abuse risk. FDA Access Data

7) Tramadol.
Class: Atypical opioid/SNRI. Dose/Time: Per label limits. Purpose: Rescue for refractory pain. Mechanism: Weak μ-agonism + monoamine reuptake inhibition. Side effects: Nausea, dizziness, seizure risk, dependence. FDA Access Data

8) Amitriptyline.
Class: TCA. Dose/Time: Low-dose nightly (e.g., 10–25 mg), titrate. Purpose: Neuropathic pain, sleep. Mechanism: 5-HT/NE reuptake blockade and sodium-channel effects. Side effects: Anticholinergic effects, QT risk; boxed warning for suicidality. FDA Access Data+1

9) Nortriptyline (Pamelor).
Class: TCA (often better tolerated). Dose/Time: Low-dose nightly, titrate. Purpose: Neuropathic pain adjunct. Mechanism: 5-HT/NE reuptake inhibition with fewer anticholinergic effects than amitriptyline. Side effects: Dry mouth, dizziness; boxed warning. FDA Access Data+1

10) Carbamazepine (for neuralgic pain flares).
Class: Sodium-channel blocker. Dose/Time: Titrate per label with monitoring. Purpose: Paroxysmal neuralgia components. Mechanism: Stabilizes hyperexcitable membranes. Side effects: Hyponatremia, rash, drug interactions. FDA Access Data

11) Oxcarbazepine / Oxtellar XR.
Class: Sodium-channel blocker. Dose/Time: Per label. Purpose: Alternative to carbamazepine for neuralgic pain features (off-label). Mechanism: Na⁺ channel modulation. Side effects: Hyponatremia, dizziness. FDA Access Data+1

12) NSAIDs (e.g., Naproxen).
Class: Non-steroidal anti-inflammatory. Dose/Time: Per label for musculoskeletal pain flares; not primary for neuropathic pain. Purpose: Treat secondary joint/soft tissue pain from deformity or overuse. Mechanism: COX inhibition. Side effects: GI/renal/cardiovascular risks (boxed warning). FDA Access Data+1

13) Baclofen (spasticity/cramps in select patients).
Class: GABA_B agonist. Dose/Time: Titrate slowly; oral solutions exist. Purpose: Reduce muscle cramps/spasticity that may coexist. Mechanism: Inhibits spinal reflexes. Side effects: Sedation, weakness. FDA Access Data

14) Tizanidine.
Class: α2-adrenergic agonist. Dose/Time: Titrate per label. Purpose: Alternate antispasmodic. Mechanism: Reduces polysynaptic spinal reflex activity. Side effects: Hypotension, sedation, LFT changes. FDA Access Data

15) Topical lidocaine/capsaicin combinations (sequenced care).
Class: Local analgesics. Dose/Time: As labeled/clinic applied. Purpose: Add-on when systemic drugs limited. Mechanism: Peripheral nociceptor modulation. Side effects: Local irritation. FDA Access Data+1

16) Duloxetine + pregabalin combination (when monotherapy inadequate).
Class: SNRI + gabapentinoid. Dose/Time: Conservative titration. Purpose: Address multiple pain pathways. Mechanism: Central and presynaptic modulation. Side effects: Additive dizziness/somnolence. American Academy of Neurology

17) Tricyclic at bedtime with daytime gabapentinoid (careful).
Purpose/Mechanism: Sleep consolidation + daytime pain control; monitor anticholinergic/QT risks. FDA Access Data

18) Tapentadol short-term bridge to non-opioids (severe flares).
Purpose/Mechanism: Short course while optimizing non-opioids; observe opioid safety. FDA Access Data

19) Midodrine (if disabling orthostatic lightheadedness).
Class: α1-agonist. Dose/Time: Per label. Purpose: Raises standing BP to improve function if autonomic features occur. Side effects: Supine hypertension, piloerection. FDA Access Data

20) Droxidopa (Northera) (select autonomic cases).
Class: NE precursor. Dose/Time: Per label titration. Purpose: Symptomatic neurogenic orthostatic hypotension to aid rehab participation. Side effects: Headache, hypertension. FDA Access Data

Important safety note for CMT: Avoid or use extreme caution with vincristine and possibly paclitaxel, which can severely worsen neuropathy in CMT; discuss alternatives with oncology teams. PubMed+1

---

Dietary molecular supplements

1) Alpha-lipoic acid (ALA).
Dose: Commonly 600 mg/day in trials. Function/Mechanism: Antioxidant improving redox balance; mixed evidence—some RCTs suggested symptom benefits in diabetic neuropathy, while recent reviews question clinical impact. PubMed+2PMC+2

2) Acetyl-L-carnitine (ALC).
Dose: Often 1–3 g/day. Function/Mechanism: Mitochondrial fatty-acid transport; some trials showed improved pain/nerve regeneration, others were negative—use is individualized. PubMed+1

3) Coenzyme Q10.
Dose: 100–300 mg/day. Function/Mechanism: Supports electron-transport chain; preclinical/clinical signals for neuroprotection exist, but high-quality neuropathy data remain limited. PMC+1

4) Vitamin D.
Dose: Based on deficiency; often 1000–4000 IU/day under supervision. Function/Mechanism: Immunomodulation and nociceptive pathway modulation; some studies suggest pain improvement, others are inconclusive. BMJ Dr. Care+1

5) Omega-3 fatty acids (EPA/DHA).
Dose: Frequently 1–3 g/day (combined EPA/DHA). Function/Mechanism: Anti-inflammatory/neuroprotective; limited neuropathy evidence but some studies show corneal nerve fiber improvement; balance benefits vs. risks. American Academy of Neurology+1

6) N-acetylcysteine (NAC).
Dose: 600–1200 mg/day. Function/Mechanism: Glutathione precursor; theoretical antioxidant support in mitochondrial stress (evidence in neuropathy is emergent). PMC

7) Magnesium (if low).
Dose: Per lab guidance (e.g., 200–400 mg elemental/day). Function/Mechanism: Neuromuscular stabilization; helps cramps in some people. Lippincott Journals

8) B-complex (especially B12 if deficient).
Dose: Per deficiency state. Function/Mechanism: Myelin/axon metabolism support; corrects overlapping acquired neuropathies. American Academy of Neurology

9) Curcumin.
Dose: Standardized extracts (e.g., 500–1000 mg/day). Function/Mechanism: Anti-inflammatory/antioxidant; human neuropathy data limited but biologically plausible. PMC

10) Resveratrol.
Dose: 150–500 mg/day commonly used in studies. Function/Mechanism: SIRT-related mitochondrial effects; clinical neuropathy evidence limited. PMC

Note: Supplements can interact with medicines (e.g., high-dose omega-3 with anticoagulants). Coordinate with your clinician. onf.ons.org

---

Immunity-booster / regenerative / stem-cell”–type drugs

1) Intravenous immunoglobulin (IVIG) – FDA-approved for immune neuropathies, not hereditary CMT; occasionally used if a superimposed immune neuropathy is suspected. Mechanism: Immune modulation; dose per label for approved indications. Function: Treats autoimmune neuropathies, not genetic CMT. Caution: Infusion reactions, thrombosis risk. American Academy of Neurology

2) Botulinum toxin (onabotulinumtoxinA) – FDA-labeled for focal spasticity; may ease painful dystonic postures but does not fix neuropathy. Mechanism: Blocks acetylcholine release; dose per label. Function: Symptom relief in select patterns. Caution: Weakness spread. American Academy of Neurology

3) Baclofen (oral) – already listed; mechanism GABA_B agonist; dose per label; function reduces cramps/spasticity; caution sedation/weakness. FDA Access Data

4) Tizanidine – as above; α2 agonist; dose per label; function antispasmodic support; caution hypotension/sedation. FDA Access Data

5) Midodrine – for orthostatic hypotension; not regenerative but supports function so patients can participate in rehab; dose per label; caution supine hypertension. FDA Access Data

6) Droxidopa – for neurogenic orthostatic hypotension; dose per label; function symptomatic; caution headache/hypertension. FDA Access Data

Bottom line: No FDA-approved stem-cell or regenerative drug for this CMT subtype yet; management is multidisciplinary and supportive. NCBI

---

Surgeries (what they are & why)

1) Soft-tissue balancing with tendon transfers (e.g., posterior tibial to dorsum).
Procedure: Re-route tendons to restore dorsiflexion and correct varus. Why: Addresses foot-drop and cavovarus from muscle imbalance, improving plantigrade stance. PMC

2) Plantar fascia release.
Procedure: Lengthen tight fascia through small incisions. Why: Reduces cavus rigidity and forefoot overload as part of stepwise correction. EOR

3) First-metatarsal dorsiflexion osteotomy.
Procedure: Cut and realign first metatarsal to lower arch height. Why: Corrects forefoot-driven cavus and improves weight distribution. UC School of Medicine

4) Calcaneal osteotomy (lateralizing/valgus).
Procedure: Realign heel bone to correct hindfoot varus. Why: Restores mechanical axis and ankle stability in cavovarus. PMC

5) Fusion procedures (triple/hindfoot arthrodesis) in rigid deformity.
Procedure: Fuse selected joints when deformity is stiff or arthritic. Why: Achieve a plantigrade, pain-free foot when joint-preserving options are not possible. enmc.org

Surgical goals: plantigrade, stable, pain-reduced foot with preserved function whenever possible; procedures are tailored to deformity flexibility and patient goals. Mayo Clinic

---

Preventions

1. Early bracing/orthotic support to prevent falls. PubMed

2. Daily foot checks and protective footwear to avoid ulcers. RSNA Publications

3. Regular, supervised exercise to maintain strength and balance. Wiley Online Library

4. Home fall-proofing (lighting, rails, remove clutter). PubMed

5. Avoid or use great caution with vincristine / consider alternatives to paclitaxel (oncology discussion). PubMed

6. Weight management to reduce joint stress. Lippincott Journals

7. Prompt treatment of superimposed compressive neuropathies (e.g., carpal tunnel). Karger Publishers

8. Routine orthotist follow-up to maintain AFO comfort/compliance. PMC

9. Skin care for pressure areas under braces. RSNA Publications

10. Vaccination, good sleep, and general health maintenance to support training capacity and recovery. Lippincott Journals

---

When to see doctors

Seek medical care when you notice new or worsening foot-drop, frequent falls, ulcers/blisters, significant foot pain or deformity, hand weakness affecting daily tasks, or numbness spreading upward. Get urgent help for sudden severe pain, infections, or if you start a known neurotoxic drug (e.g., vincristine). A neurologist (for diagnosis and electrodiagnostics), geneticist (for testing/counseling), physiatrist/physiotherapist (for rehab), orthotist (for AFOs), and orthopedic foot/ankle surgeon (for deformities) work together for best outcomes. NCBI+1

---

What to eat / what to avoid

Eat: A balanced diet with adequate protein, colorful vegetables, whole grains, and omega-3–rich foods (fish, flax, walnuts) to support training and weight control. Correct vitamin D or B12 deficiencies if present. Hydrate well for cramp prevention. American Academy of Neurology+1

Avoid/limit: Excess calories that add joint load, heavy alcohol that can worsen neuropathy, and unsupervised high-dose supplements that may interact with medicines (e.g., omega-3 with anticoagulants). Always coordinate supplements with your clinician. onf.ons.org

---

Frequently asked questions

1) Is this caused by low dietary copper?
No. It results from cellular copper-handling defects in mitochondria (e.g., SCO2) rather than not eating enough copper. PMC

2) Can supplements cure it?
No supplement cures hereditary CMT. Some (ALA, ALC, omega-3, vitamin D) may help symptoms in select people, with mixed evidence. Cochrane Library+1

3) Are there FDA-approved disease-modifying drugs?
None for this CMT subtype. Care is supportive with rehab, bracing, pain control, and surgery if needed. NCBI

4) What proves the diagnosis?
Genetic testing confirming biallelic variants (e.g., SCO2/COX6A1) plus axonal findings on NCS/EMG. clinicalgenome.org+1

5) Will exercise make it worse?
Appropriately supervised exercise is safe and can improve strength/balance; avoid over-fatigue of very weak muscles. Wiley Online Library

6) Do AFOs really help?
Yes—AFOs can reduce tripping and improve gait efficiency; comfort and fit matter for adherence. PubMed+1

7) When is surgery considered?
When bracing and therapy aren’t enough and deformity becomes rigid or painful, surgery can realign and rebalance the foot. PMC

8) Are some medicines dangerous?
Vincristine (and possibly paclitaxel) can be unusually harmful in CMT; oncology teams should plan carefully. PubMed

9) Can pain be controlled without opioids?
Often yes—duloxetine, pregabalin, gabapentin, TCAs, topical lidocaine/capsaicin are first-line options per guidelines. American Academy of Neurology

10) Will I need a wheelchair?
Many people walk lifelong with therapy and bracing. Some need aids during flares or later; early rehab helps preserve mobility. PubMed

11) Can children be tested?
Genetic testing is appropriate when results change care (rehab planning, family counseling). Discuss timing with genetics teams. Charcot-Marie-Tooth Association

12) What about pregnancy?
Plan ahead for braces, fall prevention, and medication review (e.g., avoid teratogenic drugs). Coordinate neurology-obstetrics care. American Academy of Neurology

13) Are there clinical trials?
Trials in CMT vary by subtype; check registries and patient organizations for updates. Evidence in SCO2-related CMT is emerging. Charcot-Marie-Tooth News

14) Does weight matter?
Yes—healthy weight reduces foot stress and improves energy for training. Lippincott Journals

15) Can orthostatic dizziness be treated?
Yes—midodrine or droxidopa may help selected patients alongside fluids, salt (if appropriate), and compression wear.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 05, 2025.